Mixed results with baricitinib in biological-resistant adult-onset Still’s disease and undifferentiated systemic autoinflammatory disease
Mark Kačar, John Fitton, Andrew Gough, Maya H Buch, Dennis McGonagle, Sinisa Savic
Abstract
This clinical case series describes our experience with the use of Janus kinase 1/2 inhibitor baricitinib in two patients suffering from refractory adult-onset Still’s disease (AOSD) as well as in one case suffering from AOSD-like autoinflammatory disease in the context of myelodysplastic syndrome. All patients suffered from disease non-responsive to conventional Disease-modifying antirheumatic drugs (DMARDs) as well as biological therapies including interleukin (IL)-1 and IL-6 blockade, relying instead on high daily doses of prednisolone. We also report the first case of Pneumocystis jirovecii infection following baricitinib use.
Topics & Concepts
MedicineContext (archaeology)DiseaseAnakinraPrednisoloneRefractory (planetary science)Pneumocystis jiroveciiAdult-onset Still's diseaseDermatologyInternal medicineImmunologyHuman immunodeficiency virus (HIV)PaleontologyAstrobiologyBiologyPhysicsAutoimmune and Inflammatory Disorders ResearchPneumocystis jirovecii pneumonia detection and treatmentOtitis Media and Relapsing Polychondritis